Summary

The flow cytometry market is expected to reach USD 10.57 billion by 2034 from USD 5.56 billion in 2026, at a CAGR of 8.4% during the forecast period. The market is expected to grow steadily during the forecast period, driven by increasing use of flow cytometry in immunology, oncology, hematology, drug discovery, cell and gene therapy, and clinical diagnostics. Technologies such as conventional flow cytometry, spectral flow cytometry, imaging/hybrid flow cytometry, and bead-based flow cytometry enable detailed analysis of cell phenotype, viability, apoptosis, cell cycle, intracellular proteins, cytokines, and other functional characteristics. These technologies support applications across cancer diagnostics, autoimmune disease assessment, stem cell research, in vitro toxicity testing, cell sorting, vaccine manufacturing, CGT manufacturing, and other biologics manufacturing. The growing use of high-parameter analyzers, spectral systems, complex antibody-dye conjugates, multiplex assays, and automated data analysis is further strengthening adoption across pharmaceutical, biotechnology, academic, clinical, and CRO/CDMO settings. In addition, recurring demand for antibodies, assays & kits, controls, calibration reagents, sheath fluids, and other consumables is supporting sustained market growth. However, the market continues to face challenges related to the high cost of advanced instruments, the complexity of multicolor panel design, the need for skilled operators, reagent standardization, and the interpretation of high-dimensional flow cytometry data. Bead-based flow cytometry segment is expected to grow at the highest CAGR during the forecast period. The bead-based flow cytometry segment is projected to grow at the highest CAGR due to the increasing adoption of multiplex assays for simultaneous detection and quantification of multiple analytes from limited sample volumes. Bead-based platforms are increasingly used for cytokine profiling, biomarker analysis, immunoassays, and drug discovery studies, particularly in applications requiring high-throughput multiplex testing. The growing demand for efficient, scalable, and multiplexed analytical workflows across pharmaceutical, biotechnology, and research laboratories is driving segment growth. The reagents & consumables segment holds the largest share of the market. The reagents & consumables segment accounts for the largest share of the flow cytometry market, primarily due to the recurring requirement for antibodies, antibody-dye conjugates, assays & kits, buffers, controls, calibration reagents, sheath fluids, and other consumables in routine flow cytometry workflows. These products are extensively used in immunophenotyping, cytokine detection, apoptosis and cell viability analysis, multiplex assays, and other cellular studies. Their high frequency of consumption across academic, clinical, pharmaceutical, biotechnology, and CRO/CDMO laboratories supports the segment’s leading market position. The US is expected to grow at the highest CAGR during the forecast period. The US is expected to grow at the highest CAGR in the flow cytometry market due to its strong presence of leading flow cytometry manufacturers, pharmaceutical & biotechnology companies, advanced research infrastructure, and high adoption of sophisticated cell analysis technologies across research and clinical settings. Rising use of flow cytometry in oncology, immunology, hematology, drug discovery, cell & gene therapy, and clinical diagnostics is driving market growth. High-parameter analyzers, spectral flow cytometry systems, cell sorters, antibody-dye conjugates, multiplex assays, and advanced data analysis solutions are increasingly used across pharmaceutical & biotechnology companies, academic & research institutes, hospitals & clinical testing laboratories, and CROs & CDMOs. The primary interviews conducted for this report can be categorized as follows: ・By Respondent: Supply Side (70%) and Demand Side (30%) ・By Designation: Managers (45%), CXOs and Directors (30%), and Executives (25%) ・By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%) BD (US), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Bio-Rad Laboratories, Inc. (US), Sony Corporation (Japan), Miltenyi Biotec (Germany), Enzo Biochem Inc. (US), Sysmex Corporation (Japan), Cytek Biosciences (US), BIOMERIEUX (France), Cytonome/ST LLC (US), Sartorius AG (Germany), Union Biometrica, Inc. (US), Takara Bio Inc. (Japan), Revvity (US), Charles River Laboratories (US), The Jackson Laboratory (US), Apogee Flow Systems Ltd. (UK), Stratedigm, Inc (US), Nova Biomedical (US), On-chip Biotechnologies Co., Ltd. Corporation (Japan), Precision Cell Systems (US), CytoBuoy (Netherlands), CUSABIO TECHNOLOGY LLC (US), De Novo Software (US), Altasciences (Canada), RayBiotech, Inc. (US), and KCAS Bio (US) are some of the key companies offering flow cytometry products and services. Research Coverage This research report categorizes the flow cytometry market by product {reagents & consumables [antibodies (unconjugated antibodies and antibody-dye conjugates), assays & kits (phenotyping assays & kits, cytokine detection assays & kits, multiplex assays & kits, apoptosis & cell viability assays, and other assays & kits) and other reagents & consumables], instruments [cell analyzers (high-plex/high-parameter analyzers, standard benchtop/mid-parameter analyzers, and compact/low-parameter analyzers), and cell sorters (high-range cell sorters, mid-range cell sorters, and low-range cell sorters)], software, and accessories}, technology (cell-based flow cytometry and bead-based flow cytometry), detection modality (conventional flow cytometry, spectral flow cytometry, and imaging/hybrid flow cytometry), application [research applications (drug discovery, stem cell research, in vitro toxicity testing, immunology, cell sorting, apoptosis, cell cycle analysis, cell viability, cell counting, and other research applications), clinical applications (cancer diagnostics, hematology, autoimmune diseases, organ transplantation, and other clinical applications), pharmaceutical & biotechnology applications, and industrial applications], product market by end user (academic & research institutes, hospitals & clinical testing laboratories, pharmaceutical & biotechnology companies, and CROs & CDMOs), service market by type (immunophenotyping services, cell sorting services, assay development services, and other services), service market by end user (academic & research institutes, hospitals & clinical testing laboratories, and pharmaceutical & biotechnology companies), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa). The report’s scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, which influence the growth of the flow cytometry market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overviews, product portfolios, key strategies, new product launches, acquisitions, and recent developments in the flow cytometry market. This report also includes a competitive analysis of emerging startups in the flow cytometry industry ecosystem. Key Benefits of Buying the Report The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and provide insights into key drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: ・Analysis of key drivers (rising adoption of flow cytometry in oncology research and diagnostics, increasing demand for high-parameter and spectral flow cytometry for multiparameter cellular analysis, growing application of flow cytometry in cell and gene therapy development and manufacturing), restraints (high cost of advanced flow cytometers), opportunities (increasing adoption of flow cytometry in clinical diagnostics and biopharmaceutical quality control, growing demand for automated and AI-enabled flow cytometry for high-throughput and complex data analysis), and challenges (complexities related to reagent development) influencing the market growth ・Product Development/Innovation: Detailed insights into newly launched products and innovations in the flow cytometry market ・Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions ・Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the flow cytometry market ・Competitive Assessment: In-depth assessment of market shares, growth strategies, and products & services of leading players, BD (US), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Bio-Rad Laboratories, Inc. (US), Sony Corporation (Japan), Miltenyi Biotec (Germany), Enzo Biochem Inc. (US), Sysmex Corporation (Japan), Cytek Biosciences (US), and Revvity (US), among others, for the flow cytometry market

ページTOPに戻る

Table of Contents

1 INTRODUCTION 58
1.1 STUDY OBJECTIVES 58
1.2 MARKET DEFINITION 58
1.3 STUDY SCOPE 58
1.3.1 MARKET SEGMENTATION AND REGIONS COVERED 59
1.3.2 INCLUSIONS & EXCLUSIONS 60
1.3.3 YEARS CONSIDERED 61
1.3.4 CURRENCY CONSIDERED 61
1.4 STAKEHOLDERS 61
1.5 SUMMARY OF CHANGES 62
2 EXECUTIVE SUMMARY 63
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 63
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 64
2.3 DISRUPTIVE TRENDS IN FLOW CYTOMETRY MARKET 65
2.4 HIGH-GROWTH SEGMENTS 66
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 67
3 PREMIUM INSIGHTS 68
3.1 FLOW CYTOMETRY MARKET OVERVIEW 68
3.2 NORTH AMERICA: FLOW CYTOMETRY MARKET, BY PRODUCT & COUNTRY 69
3.3 FLOW CYTOMETRY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 70
3.4 FLOW CYTOMETRY MARKET SHARE, BY TECHNOLOGY, 2026 VS. 2034 (%) 71
3.5 FLOW CYTOMETRY MARKET, BY OFFERING, 2024–2034 (USD MILLION) 71
4 MARKET OVERVIEW 72
4.1 INTRODUCTION 72
4.2 MARKET DYNAMICS 72
4.2.1 DRIVERS 73
4.2.1.1 Rising adoption of flow cytometry in oncology research and diagnostics 73
4.2.1.2 Increasing demand for high-parameter and spectral flow cytometry for multiparameter cellular analysis 74
4.2.1.3 Growing applications in cell & gene therapy development and manufacturing 74
4.2.2 RESTRAINTS 75
4.2.2.1 High cost of advanced flow cytometers 75
4.2.3 OPPORTUNITIES 75
4.2.3.1 Increasing adoption in clinical diagnostics and biopharmaceutical quality control 75
4.2.3.2 Growing demand for automated and AI-enabled flow cytometry for high-throughput and complex data analysis 76
4.2.4 CHALLENGES 76
4.2.4.1 Complexities related to reagent development 76
4.3 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 77
4.4 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 77
5 INDUSTRY TRENDS 79
5.1 PORTER’S FIVE FORCES ANALYSIS 79
5.1.1 INTENSITY OF COMPETITIVE RIVALRY 80
5.1.2 BARGAINING POWER OF SUPPLIERS 80
5.1.3 BARGAINING POWER OF BUYERS 81
5.1.4 THREAT FROM SUBSTITUTES 81
5.1.5 THREAT FROM NEW ENTRANTS 81
5.2 MACROECONOMIC OUTLOOK 81
5.2.1 INTRODUCTION 81
5.2.2 GDP TRENDS AND FORECAST 82
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 82
5.2.4 TRENDS IN GLOBAL BIOTECH INDUSTRY 82
5.3 VALUE CHAIN ANALYSIS 83
5.4 ECOSYSTEM ANALYSIS 84
5.4.1 ROLE OF PLAYERS IN ECOSYSTEM 86
5.5 PRICING ANALYSIS 87
5.5.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023–2025 87
5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 89
5.6 TRADE ANALYSIS 91
5.6.1 IMPORT SCENARIO (HS CODE 9027.50) 91
5.6.2 EXPORT SCENARIO (HS CODE 9027.50) 92
5.7 KEY CONFERENCES & EVENTS, 2026–2027 93
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 94
5.9 INVESTMENT & FUNDING SCENARIO 95
5.10 CASE STUDY ANALYSIS 96
5.10.1 AI-ASSISTED FLOW CYTOMETRY SUPPORTS MEASURABLE RESIDUAL DISEASE ASSESSMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA 96
5.10.2 SPECTRAL FLOW CYTOMETRY EXPANDS HIGH-DIMENSIONAL IMMUNE PROFILING 96
5.10.3 NO-WASH FLOW CYTOMETRY IMPROVES CAR-T CELL MONITORING 97
5.11 IMPACT OF 2025 US TARIFFS—FLOW CYTOMETRY MARKET 97
5.11.1 INTRODUCTION 97
5.11.2 KEY TARIFF RATES 98
5.11.3 PRICE IMPACT ANALYSIS 99
5.11.4 IMPACT ON COUNTRIES/REGIONS 99
5.11.4.1 US 99
5.11.4.2 Europe 100
5.11.4.3 Asia Pacific 100
5.11.5 IMPACT ON END-USE INDUSTRIES 100
5.11.5.1 Academic & Research Institutes 101
5.11.5.2 Hospitals & Clinical Testing Laboratories 101
5.11.5.3 Pharmaceutical & Biotechnology Companies 101
5.11.5.4 CROs & CDMOs 102
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 103
6.1 TECHNOLOGY ANALYSIS 103
6.1.1 KEY TECHNOLOGIES 103
6.1.1.1 Mass cytometry 103
6.1.1.2 Microfluidics 103
6.1.2 COMPLEMENTARY TECHNOLOGIES 104
6.1.2.1 Single-cell analysis 104
6.1.2.2 Spatial analysis 104
6.1.3 ADJACENT TECHNOLOGIES 105
6.1.3.1 Single-cell RNA sequencing 105
6.1.3.2 High-content screening 105
6.2 TECHNOLOGY ROADMAP 105
6.3 PATENT ANALYSIS 106
6.3.1 METHODOLOGY 106
6.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE 106
6.3.3 LIST OF KEY PATENTS 108
6.4 FUTURE APPLICATIONS 108
6.5 IMPACT OF AI/GEN AI ON FLOW CYTOMETRY MARKET 109
6.5.1 TOP USE CASES AND MARKET POTENTIAL 110
6.5.2 BEST PRACTICES IN AI-ENABLED FLOW CYTOMETRY DATA ANALYSIS AND INTERPRETATION 111
6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN FLOW CYTOMETRY MARKET 111
6.5.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 111
6.5.5 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED FLOW CYTOMETRY SOLUTIONS 112
7 SUSTAINABILITY AND REGULATORY LANDSCAPE 113
7.1 REGIONAL REGULATIONS AND COMPLIANCE 113
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 113
7.1.2 INDUSTRY STANDARDS 116
7.1.2.1 North America 116
7.1.2.2 Europe 116
7.1.2.3 Asia Pacific 117
7.1.2.4 Rest of the world 117
7.2 SUSTAINABILITY INITIATIVES 117
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES 118
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 118
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 121
8.1 DECISION-MAKING PROCESS 121
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 121
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 121
8.2.2 KEY BUYING CRITERIA, BY END USER 122
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 123
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 124
9 FLOW CYTOMETRY PRODUCTS MARKET, BY TYPE 125
9.1 INTRODUCTION 126
9.2 REAGENTS & CONSUMABLES 126
9.2.1 ANTIBODIES 130
9.2.1.1 Unconjugated Antibodies 134
9.2.1.1.1 Expanding assay customization and biomarker validation to drive market 134
9.2.1.2 Antibody Dye Conjugates 138
9.2.1.2.1 Expanding multicolor and spectral workflows to boost market 138
9.2.2 ASSAYS & KITS 141
9.2.2.1 Phenotyping Assays & Kits 145
9.2.2.1.1 Standardized immune profiling and expanding cell therapy characterization to drive market 145
9.2.2.2 Cytokine Detection Assays & Kits 149
9.2.2.2.1 Growing emphasis on functional immune-response assessment to boost market 149
9.2.2.3 Multiplex Assays & Kits 152
9.2.2.3.1 Broader biomarker profiling and sample-efficient testing to drive market 152
9.2.2.4 Apoptosis & Cell Viability Assays & Kits 156
9.2.2.4.1 Expanding drug-response testing and cell quality assessment to boost market 156
9.2.2.5 Other Assays & Kits 159
9.2.3 OTHER REAGENTS & CONSUMABLES 163
9.3 INSTRUMENTS 166
9.3.1 CELL ANALYZERS 170
9.3.1.1 High-Plex/ High-Parameter Analyzers 174
9.3.1.1.1 Expanding high-dimensional immune profiling and biomarker research to accelerate market growth 174
9.3.1.2 Standard Benchtop/ Mid-Parameter Analyzers 178
9.3.1.2.1 Increasing demand for accessible, compact, and simplified routine cell analysis to drive market 178
9.3.1.3 Compact/Low-Parameter Analyzers 181
9.3.1.3.1 Decentralized routine testing and demand for simpler cell analysis to expand adoption 181
9.3.2 CELL SORTERS 185
9.3.2.1 High-Range Cell Sorters 189
9.3.2.1.1 High-dimensional research and rare-cell recovery to drive market 189
9.3.2.2 Mid-Range Cell Sorters 192
9.3.2.2.1 Expanding in-house research workflows and demand for flexible, cost-efficient cell purification to drive market 192
9.3.2.3 Low-Range Cell Sorters 196
9.3.2.3.1 Affordability, ease of use, and decentralized access to boost growth 196
9.4 SOFTWARE 199
9.4.1 RISING DATA COMPLEXITY AND AUTOMATION REQUIREMENTS TO DRIVE MARKET 199
9.5 ACCESSORIES 203
9.5.1 EXPANDING INSTRUMENT INSTALLATIONS, TECHNOLOGY UPGRADES, AND CALIBRATION REQUIREMENTS TO DRIVE MARKET 203
10 FLOW CYTOMETRY PRODUCTS MARKET, BY TECHNOLOGY 207
10.1 INTRODUCTION 208
10.2 CELL-BASED FLOW CYTOMETRY 208
10.2.1 RISING DEMAND FOR HIGH-PARAMETER CELLULAR ANALYSIS TO BOOST MARKET GROWTH 208
10.3 BEAD-BASED FLOW CYTOMETRY 212
10.3.1 GROWING DEMAND FOR MULTIPLEX BIOMARKER ANALYSIS TO FUEL SEGMENT 212
11 FLOW CYTOMETRY PRODUCTS MARKET, BY DETECTION MODALITY 216
11.1 INTRODUCTION 217
11.2 CONVENTIONAL FLOW CYTOMETRY 217
11.2.1 ESTABLISHED FILTER-BASED DETECTION, VALIDATED ASSAYS, AND ROUTINE CLINICAL WORKFLOWS TO DRIVE MARKET 217
11.3 SPECTRAL FLOW CYTOMETRY 221
11.3.1 HIGH-PARAMETER ANALYSIS, SPECTRAL UNMIXING, AND EXPANDING PANEL COMPLEXITY TO PROPEL GROWTH 221
11.4 IMAGING/HYBRID FLOW CYTOMETRY 224
11.4.1 DEMAND FOR SIMULTANEOUS MORPHOLOGICAL AND FLUORESCENCE-BASED CHARACTERIZATION TO DRIVE MARKET 224
12 FLOW CYTOMETRY PRODUCTS MARKET, BY END USER 228
12.1 INTRODUCTION 229
12.2 ACADEMIC & RESEARCH INSTITUTES 229
12.2.1 EXPANDING RESEARCH INFRASTRUCTURE TO BOOST MARKET GROWTH 229
12.3 HOSPITALS & CLINICAL TESTING LABORATORIES 233
12.3.1 EXPANDING CLINICAL DIAGNOSTICS AND DISEASE MONITORING TO FUEL SEGMENT 233
12.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 236
12.4.1 EXPANDING DRUG DISCOVERY AND CELL THERAPY PIPELINES TO DRIVE MARKET 236
12.5 CROS & CDMOS 240
12.5.1 RISING OUTSOURCING OF COMPLEX BIOANALYTICAL WORKFLOWS TO DRIVE GROWTH 240
13 FLOW CYTOMETRY SERVICES MARKET, BY TYPE 244
13.1 INTRODUCTION 245
13.2 IMMUNOPHENOTYPING SERVICES 245
13.2.1 EXPANDING BIOMARKER-DRIVEN TRIALS AND ADVANCED THERAPIES TO BOOST MARKET GROWTH 245
13.3 CELL SORTING SERVICES 249
13.3.1 INCREASING DEMAND FOR RARE-CELL ISOLATION, SINGLE-CELL WORKFLOWS, AND ADVANCED SPECTRAL SORTING TO FUEL SEGMENT 249
13.4 ASSAY DEVELOPMENT SERVICES 252
13.4.1 INCREASING THERAPEUTIC COMPLEXITY AND DEMAND FOR VALIDATED, CUSTOMIZED HIGH-PARAMETER ASSAYS TO DRIVE MARKET 252
13.5 OTHER SERVICES 256
14 FLOW CYTOMETRY SERVICES MARKET, BY END USER 260
14.1 INTRODUCTION 261
14.2 ACADEMIC & RESEARCH INSTITUTES 261
14.2.1 EXPANDING ACCESS TO SPECIALIZED CYTOMETRY EXPERTISE TO BOOST MARKET GROWTH 261
14.3 HOSPITALS & CLINICAL TESTING LABORATORIES 265
14.3.1 RISING DEMAND FOR SPECIALIZED CLINICAL TESTING TO FUEL SEGMENT 265
14.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 268
14.4.1 EXPANDING OUTSOURCING OF COMPLEX BIOANALYTICAL TESTING TO DRIVE MARKET 268
15 FLOW CYTOMETRY MARKET, BY APPLICATION 272
15.1 INTRODUCTION 273
15.2 RESEARCH APPLICATIONS 273
15.2.1 DRUG DISCOVERY 277
15.2.1.1 High-throughput cellular screening and deeper phenotypic analysis to boost market growth 277
15.2.2 STEM CELL RESEARCH 281
15.2.2.1 Expanding iPSC research to drive market 281
15.2.3 IN VITRO TOXICITY TESTING 284
15.2.3.1 Growing mechanistic safety testing to drive market 284
15.2.4 IMMUNOLOGY 288
15.2.4.1 High-dimensional immune profiling to aid market growth 288
15.2.5 CELL SORTING 291
15.2.5.1 Rare-cell isolation and integration with downstream single-cell analysis to drive market 291
15.2.6 APOPTOSIS 295
15.2.6.1 Expanding cancer therapy research to propel market growth 295
15.2.7 CELL CYCLE ANALYSIS 298
15.2.7.1 Expanding cell cycle-targeted drug research to drive market 298
15.2.8 CELL VIABILITY 302
15.2.8.1 Growing cell-based research and increasing emphasis on standardized cell quality assessment to drive market growth 302
15.2.9 CELL COUNTING 305
15.2.9.1 Increasing demand for accurate population-specific quantification to drive market 305
15.2.10 OTHER RESEARCH APPLICATIONS 309
15.3 CLINICAL APPLICATIONS 311
15.3.1 CANCER DIAGNOSTICS 315
15.3.1.1 High-parameter cancer immunophenotyping and expanding residual disease assessment to drive market 315
15.3.2 HEMATOLOGY 319
15.3.2.1 Expanding stem cell transplantation and specialized blood cell assessment to propel market growth 319
15.3.3 AUTOIMMUNE DISEASES 322
15.3.3.1 Advanced immune profiling and biomarker-based patient stratification to drive market 322
15.3.4 ORGAN TRANSPLANTATION 326
15.3.4.1 Increasing demand for sensitive donor-recipient compatibility assessment to drive market 326
15.3.5 OTHER CLINICAL APPLICATIONS 329
15.4 PHARMACEUTICAL & BIOTECHNOLOGY APPLICATIONS 333
15.4.1 HIGH-THROUGHPUT DRUG DISCOVERY AND EXPANDING ADVANCED THERAPY DEVELOPMENT TO DRIVE MARKET 333
15.5 INDUSTRIAL APPLICATIONS 336
15.5.1 DEMAND FOR RAPID MICROBIAL QUALITY ASSESSMENT TO DRIVE MARKET 336
16 FLOW CYTOMETRY MARKET, BY REGION 340
16.1 INTRODUCTION 341
16.2 NORTH AMERICA 341
16.2.1 US 350
16.2.1.1 Advanced biomedical research and expanding cell therapy development to drive market 350
16.2.2 CANADA 357
16.2.2.1 Public research investment and expanding advanced cellular research to boost market growth 357
16.3 EUROPE 364
16.3.1 GERMANY 372
16.3.1.1 Research infrastructure investment and growing high-dimensional cellular studies to aid market growth 372
16.3.2 UK 379
16.3.2.1 Research infrastructure funding and expanding translational science to spur market growth 379
16.3.3 FRANCE 385
16.3.3.1 Public research infrastructure investment and advanced oncology research to fuel market growth 385
16.3.4 ITALY 392
16.3.4.1 Research infrastructure modernization to boost market growth 392
16.3.5 SPAIN 398
16.3.5.1 Advanced hematology diagnostics and expanding translational research to augment market growth 398
16.3.6 REST OF EUROPE 404
16.4 ASIA PACIFIC 411
16.4.1 CHINA 421
16.4.1.1 Expanding cell therapy research, clinical adoption, and localized instrument manufacturing to support market growth 421
16.4.2 JAPAN 427
16.4.2.1 Regenerative medicine leadership and investment in advanced shared cytometry infrastructure to drive market 427
16.4.3 INDIA 434
16.4.3.1 Expanding biopharma research and access to advanced cytometry infrastructure to drive market 434
16.4.4 AUSTRALIA 441
16.4.4.1 Research infrastructure modernization and expanding precision medicine to propel market growth 441
16.4.5 SOUTH KOREA 447
16.4.5.1 Increasing adoption of high-dimensional cellular analysis to spur market growth 447
16.4.6 SINGAPORE 454
16.4.6.1 Biomedical research investment and localization of advanced cytometry manufacturing to drive market 454
16.4.7 INDONESIA 461
16.4.7.1 Healthcare modernization and expanding biomedical research to drive market 461
16.4.8 REST OF ASIA PACIFIC 467
16.5 LATIN AMERICA 474
16.5.1 BRAZIL 481
16.5.1.1 Expanding advanced biomedical research and modernization of shared cytometry infrastructure to boost market growth 481
16.5.2 MEXICO 487
16.5.2.1 Expanding shared research infrastructure to fuel market growth 487
16.5.3 REST OF LATIN AMERICA 493
16.6 MIDDLE EAST 500
16.6.1 GCC COUNTRIES 506
16.6.1.1 Saudi Arabia 513
16.6.1.1.1 Advanced hematology diagnostics to boost market growth 513
16.6.1.2 UAE 519
16.6.1.2.1 Expanding advanced diagnostic infrastructure to drive market 519
16.6.1.3 Rest of GCC countries 525
16.6.2 REST OF MIDDLE EAST 531
16.7 AFRICA 537
16.7.1 PUBLIC HEALTH INVESTMENT AND EXPANDING BIOMEDICAL RESEARCH INFRASTRUCTURE TO PROPEL MARKET GROWTH 537
17 COMPETITIVE LANDSCAPE 545
17.1 INTRODUCTION 545
17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021–2025 545
17.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN FLOW CYTOMETRY MARKET, JANUARY 2023–JULY 2026 545
17.3 REVENUE ANALYSIS, 2021–2025 546
17.4 MARKET SHARE ANALYSIS, 2025 547
17.5 BRAND COMPARISON 550
17.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 551
17.6.1 STARS 551
17.6.2 EMERGING LEADERS 551
17.6.3 PERVASIVE PLAYERS 551
17.6.4 PARTICIPANTS 551
17.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 553
17.6.5.1 Company footprint 553
17.6.5.2 Region footprint 554
17.6.5.3 Product & service footprint 555
17.6.5.4 Technology footprint 556
17.6.5.5 Application footprint 557
17.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 557
17.7.1 PROGRESSIVE COMPANIES 558
17.7.2 RESPONSIVE COMPANIES 558
17.7.3 DYNAMIC COMPANIES 558
17.7.4 STARTING BLOCKS 558
17.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 560
17.7.5.1 Detailed list of key startup/SME players 560
17.7.5.2 Competitive benchmarking of startups/SMEs 560
17.8 COMPANY VALUATION AND FINANCIAL METRICS 561
17.8.1 COMPANY VALUATION 561
17.8.2 FINANCIAL METRICS 562
17.9 COMPETITIVE SCENARIO 562
17.9.1 PRODUCT LAUNCHES 562
17.9.2 DEALS 563
18 COMPANY PROFILES 564
18.1 KEY PLAYERS 564
18.1.1 BD 564
18.1.1.1 Business overview 564
18.1.1.2 Products/services/solutions offered 565
18.1.1.3 Recent developments 569
18.1.1.3.1 Product launches and product enhancements 569
18.1.1.3.2 Deals 570
18.1.1.4 MnM view 570
18.1.1.4.1 Right to win 570
18.1.1.4.2 Strategic choices 570
18.1.1.4.3 Weaknesses & competitive threats 570
18.1.2 DANAHER CORPORATION 571
18.1.2.1 Business overview 571
18.1.2.2 Products/services/solutions offered 572
18.1.2.3 Recent developments 574
18.1.2.3.1 Product launches 574
18.1.2.3.2 Deals 575
18.1.2.4 MnM view 575
18.1.2.4.1 Right to win 575
18.1.2.4.2 Strategic choices 575
18.1.2.4.3 Weaknesses & competitive threats 575
18.1.3 THERMO FISHER SCIENTIFIC INC. 576
18.1.3.1 Business overview 576
18.1.3.2 Products/services/solutions offered 577
18.1.3.3 Recent developments 578
18.1.3.3.1 Product launches 578
18.1.3.4 MnM view 579
18.1.3.4.1 Right to win 579
18.1.3.4.2 Strategic choices 579
18.1.3.4.3 Weaknesses & competitive threats 579
18.1.4 REVVITY 580
18.1.4.1 Business overview 580
18.1.4.2 Products/services/solutions offered 581
18.1.4.3 MnM view 582
18.1.4.3.1 Right to win 582
18.1.4.3.2 Strategic choices 582
18.1.4.3.3 Weaknesses & competitive threats 582
18.1.5 AGILENT TECHNOLOGIES, INC. 583
18.1.5.1 Business overview 583
18.1.5.2 Products/services/solutions offered 584
18.1.5.3 Recent developments 585
18.1.5.3.1 Product launches 585
18.1.6 SONY GROUP CORPORATION 586
18.1.6.1 Business overview 586
18.1.6.2 Products/services/solutions offered 587
18.1.6.3 Recent developments 589
18.1.6.3.1 Product launches 589
18.1.6.3.2 Deals 589
18.1.7 BIO-RAD LABORATORIES, INC. 590
18.1.7.1 Business overview 590
18.1.7.2 Products/Services/Solutions offered 591
18.1.7.3 Recent developments 592
18.1.7.3.1 Product launches 592
18.1.8 MILTENYI BIOTEC 593
18.1.8.1 Business overview 593
18.1.8.2 Products/services/solutions offered 593
18.1.9 ENZO BIOCHEM, INC. 595
18.1.9.1 Business overview 595
18.1.9.2 Products/services/solutions offered 595
18.1.10 SYSMEX CORPORATION 597
18.1.10.1 Business overview 597
18.1.10.2 Products/services/solutions offered 599
18.1.11 CYTEK BIOSCIENCES, INC. 600
18.1.11.1 Business overview 600
18.1.11.2 Products/services/solutions offered 601
18.1.11.3 Recent developments 603
18.1.11.3.1 Product launches 603
18.1.11.3.2 Deals 603
18.1.12 BIOMÉRIEUX 605
18.1.12.1 Business overview 605
18.1.12.2 Products/services/solutions offered 606
18.1.12.3 Recent developments 607
18.1.12.3.1 Deals 607
18.1.13 CYTONOME/ST, LLC 608
18.1.13.1 Business overview 608
18.1.13.2 Products/services/solutions offered 608
18.1.14 SARTORIUS AG 609
18.1.14.1 Business overview 609
18.1.14.2 Products/services/solutions offered 610
18.1.14.3 Recent developments 611
18.1.14.3.1 Product launches 611
18.1.15 UNION BIOMETRICA, INC. 612
18.1.15.1 Business overview 612
18.1.15.2 Products/services/solutions offered 612
18.1.16 TAKARA BIO INC. 613
18.1.16.1 Business overview 613
18.1.16.2 Products/services/solutions offered 614
18.1.17 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 615
18.1.17.1 Business overview 615
18.1.17.2 Products/services/solutions offered 616
18.1.18 THE JACKSON LABORATORY 617
18.1.18.1 Business overview 617
18.1.18.2 Products/services/solutions offered 618
18.2 OTHER PLAYERS 619
18.2.1 APOGEE FLOW SYSTEMS LTD 619
18.2.2 STRATEDIGM, INC. 620
18.2.3 NOVA BIOMEDICAL CORPORATION 621
18.2.4 ON-CHIP BIOTECHNOLOGIES CO., LTD. 622
18.2.5 PRECISION CELL SYSTEMS, INC. 623
18.2.6 CYTOBUOY B.V. 624
18.2.7 CUSABIO TECHNOLOGY LLC 624
18.2.8 DE NOVO SOFTWARE 625
18.2.9 ALTASCIENCES 625
18.2.10 RAYBIOTECH, INC. 626
18.2.11 KCAS BIO 626
19 RESEARCH METHODOLOGY 627
19.1 RESEARCH DATA 627
19.1.1 SECONDARY DATA 628
19.1.1.1 Key data from secondary sources 628
19.1.2 PRIMARY DATA 629
19.1.2.1 Key data from primary sources 629
19.1.2.2 Key primary participants 629
19.1.2.3 Breakdown of primary interviews 629
19.1.2.4 Key industry insights 630
19.2 MARKET SIZE ESTIMATION 630
19.2.1 GLOBAL FLOW CYTOMETRY MARKET ESTIMATION, 2025 631
19.2.2 SEGMENTAL MARKET SIZE ESTIMATION 634
19.3 MARKET GROWTH RATE PROJECTIONS 636
19.4 DATA TRIANGULATION 637
19.5 FACTOR ANALYSIS 638
19.6 RESEARCH ASSUMPTIONS 638
19.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT 639
20 APPENDIX 640
20.1 DISCUSSION GUIDE 640
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 645
20.3 CUSTOMIZATION OPTIONS 647
20.4 RELATED REPORTS 647
20.5 AUTHOR DETAILS 648